These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 21131350)
1. Aberrant corepressor interactions implicated in PML-RAR(alpha) and PLZF-RAR(alpha) leukemogenesis reflect an altered recruitment and release of specific NCoR and SMRT splice variants. Mengeling BJ; Phan TQ; Goodson ML; Privalsky ML J Biol Chem; 2011 Feb; 286(6):4236-47. PubMed ID: 21131350 [TBL] [Abstract][Full Text] [Related]
2. SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor alpha (RARalpha) and PLZF-RARalpha oncoproteins associated with acute promyelocytic leukemia. Hong SH; David G; Wong CW; Dejean A; Privalsky ML Proc Natl Acad Sci U S A; 1997 Aug; 94(17):9028-33. PubMed ID: 9256429 [TBL] [Abstract][Full Text] [Related]
3. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Guidez F; Ivins S; Zhu J; Söderström M; Waxman S; Zelent A Blood; 1998 Apr; 91(8):2634-42. PubMed ID: 9531570 [TBL] [Abstract][Full Text] [Related]
4. Interactions of STAT5b-RARalpha, a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways. Dong S; Tweardy DJ Blood; 2002 Apr; 99(8):2637-46. PubMed ID: 11929748 [TBL] [Abstract][Full Text] [Related]
5. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Grignani F; De Matteis S; Nervi C; Tomassoni L; Gelmetti V; Cioce M; Fanelli M; Ruthardt M; Ferrara FF; Zamir I; Seiser C; Grignani F; Lazar MA; Minucci S; Pelicci PG Nature; 1998 Feb; 391(6669):815-8. PubMed ID: 9486655 [TBL] [Abstract][Full Text] [Related]
6. Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha. Cheng GX; Zhu XH; Men XQ; Wang L; Huang QH; Jin XL; Xiong SM; Zhu J; Guo WM; Chen JQ; Xu SF; So E; Chan LC; Waxman S; Zelent A; Chen GQ; Dong S; Liu JX; Chen SJ Proc Natl Acad Sci U S A; 1999 May; 96(11):6318-23. PubMed ID: 10339585 [TBL] [Abstract][Full Text] [Related]
7. PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter. Tabe Y; Konopleva M; Kondo Y; Contractor R; Jin L; Ruvolo V; Tsutsumi-Ishii Y; Miyake K; Miyake N; Ohsaka A; Nagaoka I; Issa JP; Andreeff M Ann Hematol; 2006 Oct; 85(10):689-704. PubMed ID: 16832676 [TBL] [Abstract][Full Text] [Related]
8. Acute promyelocytic leukemia with a PLZF-RARalpha fusion protein. Jansen JH; Löwenberg B Semin Hematol; 2001 Jan; 38(1):37-41. PubMed ID: 11172538 [TBL] [Abstract][Full Text] [Related]
9. The impact of differential binding of wild-type RARalpha, PML-, PLZF- and NPM-RARalpha fusion proteins towards transcriptional co-activator, RIP-140, on retinoic acid responses in acute promyelocytic leukemia. So CW; Dong S; So CK; Cheng GX; Huang QH; Chen SJ; Chan LC Leukemia; 2000 Jan; 14(1):77-83. PubMed ID: 10637480 [TBL] [Abstract][Full Text] [Related]
10. Components of the SMRT corepressor complex exhibit distinctive interactions with the POZ domain oncoproteins PLZF, PLZF-RARalpha, and BCL-6. Wong CW; Privalsky ML J Biol Chem; 1998 Oct; 273(42):27695-702. PubMed ID: 9765306 [TBL] [Abstract][Full Text] [Related]
12. Targeting the acute promyelocytic leukemia-associated fusion proteins PML/RARα and PLZF/RARα with interfering peptides. Beez S; Demmer P; Puccetti E PLoS One; 2012; 7(11):e48636. PubMed ID: 23152790 [TBL] [Abstract][Full Text] [Related]
13. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Lin RJ; Evans RM Mol Cell; 2000 May; 5(5):821-30. PubMed ID: 10882118 [TBL] [Abstract][Full Text] [Related]
14. Promyelocytic leukemia zinc finger-retinoic acid receptor α (PLZF-RARα), an oncogenic transcriptional repressor of cyclin-dependent kinase inhibitor 1A (p21WAF/CDKN1A) and tumor protein p53 (TP53) genes. Choi WI; Yoon JH; Kim MY; Koh DI; Licht JD; Kim K; Hur MW J Biol Chem; 2014 Jul; 289(27):18641-56. PubMed ID: 24821728 [TBL] [Abstract][Full Text] [Related]
15. Synthetic retinoids dissociate coactivator binding from corepressor release. Zechel C J Recept Signal Transduct Res; 2002; 22(1-4):31-61. PubMed ID: 12503607 [TBL] [Abstract][Full Text] [Related]
16. The t(5;17) acute promyelocytic leukemia fusion protein NPM-RAR interacts with co-repressor and co-activator proteins and exhibits both positive and negative transcriptional properties. Redner RL; Chen JD; Rush EA; Li H; Pollock SL Blood; 2000 Apr; 95(8):2683-90. PubMed ID: 10753851 [TBL] [Abstract][Full Text] [Related]
17. Deregulation of NPM and PLZF in a variant t(5;17) case of acute promyelocytic leukemia. Hummel JL; Wells RA; Dubé ID; Licht JD; Kamel-Reid S Oncogene; 1999 Jan; 18(3):633-41. PubMed ID: 9989813 [TBL] [Abstract][Full Text] [Related]
18. Amino-terminal protein-protein interaction motif (POZ-domain) is responsible for activities of the promyelocytic leukemia zinc finger-retinoic acid receptor-alpha fusion protein. Dong S; Zhu J; Reid A; Strutt P; Guidez F; Zhong HJ; Wang ZY; Licht J; Waxman S; Chomienne C; Chen Z; Zelent A; Chen SJ Proc Natl Acad Sci U S A; 1996 Apr; 93(8):3624-9. PubMed ID: 8622986 [TBL] [Abstract][Full Text] [Related]
19. The specificity of interactions between nuclear hormone receptors and corepressors is mediated by distinct amino acid sequences within the interacting domains. Cohen RN; Brzostek S; Kim B; Chorev M; Wondisford FE; Hollenberg AN Mol Endocrinol; 2001 Jul; 15(7):1049-61. PubMed ID: 11435607 [TBL] [Abstract][Full Text] [Related]